Levosimendan for exercise limitation in PH-HFpEF
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if the drug levosimendan can help people with a specific type of pulmonary hypertension (PH-HFpEF) feel less tired and breathless during daily activities, and improve their exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have heart failure symptoms like shortness of breath or fatigue, even with mild activity (NYHA Class II–IV).
- You have been diagnosed with a specific type of pulmonary hypertension called WHO Group 2 PH-HFpEF, confirmed by a heart catheterization.
- You have had a qualifying echocardiogram and a 6-minute walk test.
- You agree not to become pregnant or father a child during the study, and you can use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term study gives continued access to the oral levosimendan medication for people who finished the earlier TNX-103 study. The goal is to see if ongoing treatment remains safe and helpful.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This trial tests a medicine called levosimendan to see if it helps people with severe heart failure who still feel breathless at rest despite standard treatment. It may improve heart function and reduce symptoms.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests an investigational drug called VS-041 to see if it's safe and helps people with a type of heart failure where the heart pumps well but doesn't relax properly (HFpEF). It may be an option if you are 50 or older and have stable heart failure symptoms.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
Hear when a new Pulmonary Hypertension Associated With HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.